BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 17426942)

  • 1. [Benign prostate hyperplasia: success and limitations of pharmacological therapy].
    Madersbacher S; Marszalek M
    Internist (Berl); 2007 Oct; 48(10):1157-64. PubMed ID: 17426942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological treatment of benign prostatic hyperplasia].
    Oelke M; Kuczyk MA; Herrmann TR
    Urologe A; 2009 Nov; 48(11):1365-75; quiz 1376-7. PubMed ID: 19851747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological treatment of benign prostatic hyperplasia].
    Oelke M; Martinelli E
    Urologe A; 2016 Jan; 55(1):81-94; quiz 95-6. PubMed ID: 26676726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
    Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
    J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
    Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
    Morlock R; Goodwin B; Gomez Rey G; Eaddy M
    Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
    Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
    Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study.
    Mariappan P; Brown DJ; McNeill AS
    J Urol; 2007 Aug; 178(2):573-7; discussion 577. PubMed ID: 17570437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, randomized, open-label, parallel trial comparing the efficacy of α-blocker or 5α-reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Lee KS; Yoo JW; Kim DH; Jeon S; Yang J; Chung BH; Koo KC
    Prostate; 2024 Mar; 84(4):403-413. PubMed ID: 38149792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
    Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
    Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
    Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.
    Lin VC; Liao CH; Kuo HC
    Urology; 2014 Feb; 83(2):416-21. PubMed ID: 24332123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance.
    Jin R; Forbes CM; Miller NL; Lafin J; Strand DW; Case T; Cates JM; Liu Q; Ramirez-Solano M; Mohler JL; Matusik RJ
    Prostate; 2024 Apr; 84(5):441-459. PubMed ID: 38168866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptor blockers. Basic principles and clinical results].
    Oelke M; Höfner K; Berges RR; Jonas U
    Urologe A; 2002 Sep; 41(5):425-41. PubMed ID: 12426859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk stratification for benign prostatic hyperplasia (BPH) treatment.
    Emberton M; Fitzpatrick JM; Rees J
    BJU Int; 2011 Mar; 107(6):876-80. PubMed ID: 21265993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early symptom improvement and discontinuation of 5-α-reductase inhibitor (5ARI) therapy in patients with benign prostatic hyperplasia (BPH).
    Kruep EJ; Phillips E; Hogue S; Eaddy M
    Ann Pharmacother; 2014 Mar; 48(3):343-8. PubMed ID: 24311727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis.
    Kim JH; Baek MJ; Sun HY; Lee B; Li S; Khandwala Y; Del Giudice F; Chung BI
    PLoS One; 2018; 13(10):e0203479. PubMed ID: 30281615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia.
    Kang D; Hu C; Fu Y; Wang D
    Clin Invest Med; 2017 Oct; 40(5):E200-E210. PubMed ID: 29061225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.